Beam Therapeutics specializes in gene-editing medicines, and recently, the company's Senior Vice President edited out thousands of shares from her portfolio.
This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results